Rankings
▼
Calendar
MESO Q4 2020 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$692,000
-64.8% YoY
Gross Profit
-$24M
-3529.9% margin
Operating Income
-$32M
-4622.7% margin
Net Income
-$33M
-4712.4% margin
EPS (Diluted)
$-0.60
QoQ Revenue Growth
-94.3%
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$20M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$734M
Total Liabilities
$184M
Stockholders' Equity
$549M
Cash & Equivalents
$129M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$692,000
$2M
-64.8%
Gross Profit
-$24M
-$60M
+59.5%
Operating Income
-$32M
-$18M
-82.3%
Net Income
-$33M
-$21M
-57.3%
← FY 2020
All Quarters
Q1 2021 →